Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,904.50    1.00 (0.05%)
Bid:
1,904.00
Ask:
1,904.50
Spread: 0.50 (0.026%)
Market Cap: £76.35b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Amendment - Director/PDMR Shareholding

16 Apr 2024 14:11

RNS Number : 8437K
GSK PLC
16 April 2024
Β 

The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on 15 April 2024 at 15:30 under RNS No 6703K:

- A typographical correction to the share price for the transaction shown in the table below.

All other details to the original announcement remain unchanged.

The amended table is shown below.

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Amendment

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ΒΌ pence each ('Ordinary Shares')

Β 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2024, on Ordinary Shares held within an ISA

Β 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

Β£16.3860

19

d)

Aggregated information

Β 

N/A (single transaction)

Β 

Β 

Aggregated volume Price

e)

Date of the transaction

2024-04-12

f)

Place of the transaction

Β 

London Stock Exchange (XLON)

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHXQLFFZZLBBBD
Date   Source Headline
24th Nov 20223:00 pmRNSGSK publishes provisional 2023 dividend dates
22nd Nov 20224:00 pmRNSPublication of Supplementary EMTN Prospectus
22nd Nov 20227:00 amRNSBlenrep US Update
21st Nov 20223:30 pmRNSDirector/PDMR Shareholding
18th Nov 20224:00 pmRNSPublication of EMTN Supplementary Prospectus
15th Nov 20224:00 pmRNSBlock listing Interim Review
15th Nov 20223:53 pmRNSFinal results of outstanding Notes Tender Offer
15th Nov 20227:00 amRNSInterim results of outstanding Notes Tender Offer
11th Nov 20227:00 amRNSGSK Update: Zejula 2L in US
10th Nov 20226:10 pmRNSSanofi-GSK COVID booster vaccine approved by EU
10th Nov 20223:30 pmRNSDirector/PDMR Shareholding
10th Nov 20229:00 amRNSBlock Listing Application
8th Nov 20229:26 amRNSLaunch of Tender Offer for outstanding Notes
7th Nov 20227:00 amRNSDREAMM-3 phase III trial for Blenrep
3rd Nov 20221:00 pmRNSPublication of Suppl.Prospcts
3rd Nov 20227:00 amRNSIDMC recommends gepotidacin early efficacy stop
2nd Nov 20227:01 amRNS3rd Quarter Results
2nd Nov 20227:00 amRNSGSK RSV vaccine: US FDA Priority Review
1st Nov 20223:00 pmRNSTotal Voting Rights
28th Oct 20227:00 amRNSEMA accepts GSK RSV older adult vaccine for review
28th Oct 20227:00 amRNSEMA validates MAA for cabotegravir LA for PrEP
27th Oct 20227:05 amRNSGSK announces FDA meeting outcome on daprodustat
27th Oct 20227:00 amRNSContRAst phase III programme for otilimab update
25th Oct 202210:00 amRNSBoard Committee Changes
21st Oct 20227:00 amRNSRSV older adult vaccine submission in Japan
17th Oct 20227:00 amRNSMenveo new single-vial approve by US FDA
17th Oct 20227:00 amRNSMenveo new single-vial approved by US FDA
14th Oct 20222:11 pmRNSDirector/PDMR Shareholding
13th Oct 202212:46 pmRNSDirector/PDMR Shareholding
13th Oct 20229:44 amRNSDirector/PDMR Shareholding
13th Oct 20228:26 amRNSDirector/PDMR Shareholding
13th Oct 20227:00 amRNSEfficacy results for GSK’s older adult RSV vaccine
12th Oct 202211:42 amRNSDirector/PDMR Shareholding
10th Oct 20227:00 amRNSUS FDA approves Boostrix maternal immunisation
7th Oct 20224:38 pmRNSDirector/PDMR Shareholding
7th Oct 20224:24 pmRNSDirector/PDMR Shareholding
3rd Oct 202210:10 amRNSTotal Voting Rights
30th Sep 20225:21 pmRNSDirector/PDMR Shareholding
26th Sep 20225:09 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSGSK Chief Financial Officer succession
22nd Sep 20222:00 pmRNSUS FDA ODAC review of Zejula Phase III NOVA trial
22nd Sep 20227:00 amRNSGSK and Spero Therapeutics licence for tebipenem
21st Sep 202211:22 amRNSDirector/PDMR Shareholding
13th Sep 20229:11 amRNSDirector/PDMR Shareholding
9th Sep 20229:11 amRNSPublication of Base Prospectus
8th Sep 202212:58 pmRNSDirector/PDMR Shareholding
6th Sep 20221:00 pmRNSGSK provides update on FDA review of daprodustat
1st Sep 202211:48 amRNSTotal Voting Rights
24th Aug 20227:00 amRNSGSK Board changes
22nd Aug 20224:53 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.